IIA
ALNY icon

IPG Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

IPG Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,203
Closed -$217K – 168
2018
Q2 		$217K Buy
+2,203
New +$219K 0.08% 143

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IPG Investment Advisors's ALNY Position: Q3 2018 in Review

IPG Investment Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 2,203 shares — an estimated $217K sold.

IPG Investment Advisors first reported a position in ALNY in Q2 2018 and held it in 1 quarter. The position peaked at $217K in Q2 2018. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

  • IPG Investment Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • IPG Investment Advisors sold 2,203 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $217K.
  • IPG Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • IPG Investment Advisors's Alnylam Pharmaceuticals position peaked at $217K in Q2 2018.
  • 305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on IPG Investment Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.